Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany

Acta Dermato-Venereologica

Volumn 90, Issue 2, 2010, Pages 147-151

  Augustin, Matthias ^a   Reich, Kristian ^b   Glaeske, Gerd ^c   Schaefer, Ines ^a   Radtke, Marc ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Dermatologikum Hamburg   (Germany)

^c UNIVERSITY OF BREMEN   (Germany)

Author keywords

Co morbidity; Epidemiology; Healthcare; Psoriasis

Indexed keywords

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; HEALTH INSURANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; COMORBIDITY; CROHN DISEASE; GERMANY; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSURANCE, HEALTH; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PSORIASIS; YOUNG ADULT;

EID: 77950291474     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0770     Document Type: Article

References (41)

1. Schäfer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology 2006; 212: 327-337.
2. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332: 581-588.
3. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter prospective cross-sectional study in Germany. Dermatology 2008; 216: 366-372.
4. Schaefer I, Zimmer L, Rustenbach SJ, Augustin M. Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 2008; 217: 169-172.
5. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.
6. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673.
7. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 2008; 35: 1354-1358.
8. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1,511 patients with plaque-type psoriasis. Br J Dermatol 2009; 160: 1040-1047.
9. Sterry W, Strober BE, Menter A; on behalf of the International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649-655.
10. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
11. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-276.
12. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, Ståhle-Bäckdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230.
13. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-1499.
14. Setty AR, Urhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007; 167: 1670-1675.
15. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129: 827-836.
16. Wolf N, Quaranta M, Prescott NJ, Allen M, Smith R, Burden AD, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn's disease. J Med Genet 2008; 45: 114-116.
17. Häussler B, Gothe H, Mangiapane S, Glaeske G, Pientka L, Felsenberg D. Versorgung von Osteoporose-Patienten in Deutschland - Ergebnisse der BoneEVA-Studie. Dtsch Arztebl 2006; 103: A 2542-2548.
18. Sorensen HT, Sabroe S, Olsen J. A framework for evaluation of secondary data sources for epidemiological research. Int J Epidemiol 1996; 25: 435-442.
19. Schneeweiss S, Avron J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-337.
20. Rothman K, Greenland S, Lash T. Modern epidemiology. Philadelphia: Lippincott Williams and Wilkins, 2008.
21. Wittchen H, Glaesmer H, Maerz W, Stalla G, Lehnert H, Zeiher AM, et al. Cardiovascular risk factors in primary care: methods and baseline prevalence rates - the DETECT program Curr Med Res Opin 2005; 21: 619-630.
22. Stock SA, Redaelli M, Wendland G, Civello D, Lauterbach K. Diabetes - prevalence and costs of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabet Med 2006; 23: 299-305.
23. Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: A case-control study. J Am Acad Dermatol 2007; 56: 629-634.
24. Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007; 87: 506-509.
25. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
26. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159: 895-902.
27. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
28. Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009; 129: 2411-2418.
29. Delaporte E. Immune-mediated inflammatory disease and psoriasis. Ann Dermatol Venereol 2008; 135 Suppl 4: S269-S274.
30. Boehncke WH, Sterry W. Psoriasis - a systemic inflammatory disorder: clinic, pathogenesis and therapeutic perspectives. J Dtsch Dermatol Ges 2009 [Epub ahead of print].
31. Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008; 159 Suppl 2: 2-9.
32. Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009; 35: 257-259.
33. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190: 1-9.
34. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009; 160: 1048-1056.
35. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-267.
36. Jacobsson LT, Turesson C, Gülfe A, Kapetanovic MC, Petersson IF, Saxne T, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-1218.
37. Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 670-675.
38. Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges 2007; 5: 566-574.
39. Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299: 111-138.
40. Sohn S, Schöffski O, Prinz K, Schubert E, Waldorf K, Augustin M. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006; 212: 137-144.
41. Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005; 3: 511-518.